US HIFU Announces Addition Of Tissue Change Monitoring (TCM) Software To Sonablate(R) 500 Medical Device

US HIFU, LLC, introduces a new software component, called Tissue Change Monitoring (TCM), to its Sonablate(R) 500 medical device that will enhance its existing minimally invasive treatment for prostate cancer using HIFU, high intensity focused ultrasound, by enabling physicians to monitor prostatic tissue changes in real-time. Stephen Puckett, Jr., chief executive officer, US HIFU said, “TCM represents yet another major step forward for the Sonablate(R) HIFU platform.